| Name | Sodium gualenate |
| Description | Sodium gualenate (Guaiazulenesulfonate sodium) (Guaiazulenesulfonate sodium), a hydrophilic derivative of guaiazulene (GA), is an unstable compound. It has anti-inflammatory and wound-healing effects. |
| Animal Research | The anti-gastric ulcer activity of compounds was tested through an ethanol-induced gastric ulcer mouse model method.?Kunming mice, consisting of both males and females, each weighing about 25 g, were divided into groups of 8 at random.?The tested compounds, Omeprazole and guaiazulene derivatives which were made into suspensions using 5% CMC-Na were administered orally (0.4 mL/20 g) to the dose group, the drug reference group and the GAS-Na group respectively.?While the base control group was treated with only 5% CMC-Na.?Vehicle or test compounds were administered by the oral route once a day for five consecutive days.?After 0.5 h of the last dose, the mice were given orally 0.3 mL of anhydrous ethanol.?Half an hour after anhydrous ethanol administration, the animals were killed.?At last, the stomachs were removed and scored[1]. |
| In vivo | Sodium gualenate is frequently used to treat human gastritis, with its primary mechanism of action being the cytoprotection of the stomach's mucosal lining [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 30 mg/mL (99.88 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.66 mM), Sonication is recommended.
|
| Keywords | Sodium gualenate | Inhibitor | inhibit | Guaiazulenesulfonate |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
United States
